A New Treatment for Hay Fever

FDA approves prescription nasal spray Ryaltris to treat seasonal allergic rhinitis

(RxWiki News) The US Food and Drug Administration (FDA) has approved a new treatment for hay fever.

It's a prescription nasal spray called Ryaltris. The FDA approved it to treat seasonal allergic rhinitis — also known as hay fever — in adults and children who are at least 12 years old.

This nasal spray contains a combination of drugs: an antihistamine called olopatadine hydrochloride and a corticosteroid called mometasone furoate. That combination appears to reduce some of the most difficult symptoms of hay fever.

"With this ... approval, we look forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms," said Robert Crockart, chief commercial officer of drugmaker Glenmark Pharmaceuticals Limited, in a press release.

Ryaltris has already received approval in several other countries, and it was under review by Canadian health officials at the time of publication.

In clinical studies of the drug, common side effects included nose discomfort, unpleasant taste and nose bleeds. In those who have a weakened immune system, Ryaltris may increase the risk of new or worsening infections. And in pediatric patients who take Ryaltris, health officials recommended "close growth monitoring."

The FDA approved this drug for Glenmark Pharmaceuticals Limited, which is based in India. In the United States, Hikma Specialty U.S.A. Inc. will market and distribute Ryaltris.

Talk to your doctor about your options for treating seasonal allergy symptoms.

Review Date: 
January 17, 2022